oral anticoagulants
Setting priorities in the health care sector – the case of oral anticoagulants in nonvalvular atrial fibrillation in Denmark
... The analyses of the cost side in health economic analyses using a budget impact model approach have shown the importance of analyzing costs from a broader cost perspec- tive than just a focus on drug prices. For optimal ...
11
Possible failure of novel direct acting oral anticoagulants in management of pulmonary embolism: a case report
... direct-acting oral anticoagulants aim to provide a safer, more tolerable, treatment option as compared to warfarin to prevent and treat DVT, PE, and atrial fibrillation (Afib) [3, ...acting oral ...
5
Approach to the new oral anticoagulants in family practice
... • The new oral anticoagulants (NOACs) are being encountered increasingly in primary care. Although large randomized trials have addressed their efficacy and safety for stroke prevention in atrial ...
7
Novel Oral Anticoagulants for Stroke Prophylaxis and Venous Thromboembolism Prevention and Treatment
... Novel oral anticoagulants appear to offer physicians and patients multiple new options for anticoagulation in the setting of nonvalvular atrial fibrillation, deep vein thrombosis and pulmonary embolism ...
9
New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness
... management of bleeding can also be performed with these hemostatic agents. However, the effectiveness of these non- specific agents for reversing the effect anticoagulation has not been established; there are only case ...
10
New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events
... and oral anticoagulant vitamin K antagonist (VKA) drugs, the prevention and treatment of venous and arterial thrombotic phenomena remain major medical ...only oral anticoagulants used during the past ...
11
Battle of oral anticoagulants in the field of atrial fibrillation scrutinized from a clinical practice (the real world) perspective
... new oral anticoagulants that are on the market or awaiting approval or under research offer some benefits but not enough to replace warfarin until results of additional studies can show an adequate balance ...
8
Updates in the perioperative and emergency management of non vitamin K antagonist oral anticoagulants
... Perioperative management of patients treated with the non-vitamin K antagonist oral anticoagulants is an ongoing challenge. Due to the lack of good clinical studies involving adequate monitoring and ...
6
Safety of direct oral anticoagulants in patients with hereditary hemorrhagic telangiectasia
... Background: Hereditary hemorrhagic telangiectasia (HHT) is a rare vascular dysplasia resulting in visceral arteriovenous malformations and smaller mucocutaneous telangiectasia. Most patients experience recurrent ...
8
New oral anticoagulants: are coagulation units still required?
... of anticoagulants, antiplatelets given either as monotherapy or in combination for the prevention of thrombotic ...new oral anticoagulants, the pharmaceutical companies emphasize that it is not ...
6
Comparing intracerebral hemorrhages associated with direct oral anticoagulants or warfarin
... New Oral Anticoagulants 33 showed that DOAC-associated ICHs were associated with higher mortality rates, more un- favorable outcomes, and greater hematoma expansion fre- ...
9
Evaluation of bleeding in patients receiving direct oral anticoagulants
... Direct oral anticoagulants (DOACs) are recognized by evidence-based treatment guidelines as the first-line option for the treatment of venous thromboembolism and prevention of stroke and systemic embolism ...
18
Perioperative management of patients on direct oral anticoagulants
... Direct oral anticoagulants; VKAs: Vitamin K antagonists; VTE: Venous thromboembolism; NVAF: Non-valvular atrial fibrillation; CrCl: Creatinine clearance; AF: Atrial fibrillation; TE: Thrombo-embolism; ACCP: ...
17
Reversal of direct oral anticoagulants
... Abstract: Reversal agents for direct oral anticoagulants (DOACs), including factor X inhibi- tors and direct thrombin inhibitors, are a major concern in clinical practice. After DOACs were introduced and ...
6
Direct oral anticoagulants and venous thromboembolism
... direct oral anticoagulants, what have we learnt from published phase III trials regarding their efficacy and safety in the clinical setting of VTE? A number of recently published systematic reviews and ...
8
Satisfaction with oral anticoagulants in patients with atrial fibrillation
... Results: A total of 1,309 patients (mean age 78.5±8.4 years; 49.3% men; CHA 2 DS 2 VASC 4.9±1.5; HAS-BLED 2.0±0.9) were included in the study, of whom 902 (68.9%) were taking vitamin K antagonists (VKA) and 407 (31.1%) ...
8
Non Vitamin K Antagonist Oral Anticoagulants: Redefining the Role of the Nurse to Improve Patient Care
... (VKA) oral anticoagulants (OACs), including rivaroxaban, dabigatran, apixaban and edoxaban, are effective for the preven- tion of stroke in patients with non-valvular atrial fibrillation and for the ...
16
Bleeding complications from the direct oral anticoagulants
... Direct oral anticoagulants; GI: Gastrointestinal; ICH: Intracranial hemorrhage; ISTH: International society of thrombosis and haemostasis; NSAID: Non-steroidal anti-inflammatory drug; PCC: Prothrombin ...
5
Direct Oral Anticoagulants in Patients with Thrombophilia: Challenges in Diagnostic Evaluation and Treatment
... Direct oral anticoagulants (DOACs) or non-vitamin K oral anticoagulants (NOACs) are increasingly used in the prevention of recurrent venous thromboembolism (VTE), including that associated ...
10
Novel antidotes for target specific oral anticoagulants
... specific oral anticoagulants and the risk of bleeding The development of TSOAs accelerated in the last dec- ...newer oral agents to war- farin in patients with atrial ...
5